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are-Metal Versus
rug-Eluting Stent
lacement Among Patients
resenting With Anemia*
harat Koul, DO, David J. Moliterno, MD
exington, Kentucky
ultiple studies among patients with acute coronary syn-
romes (ACS) and those undergoing percutaneous coronary
ntervention (PCI) have shown that anemia is a strong
redictor for both short- and long-term adverse outcomes
1,2). In a large meta-analysis by Sabatine et al. (2) the
resence of anemia was predictive for adverse events across
he spectrum of ACS. For patients with ST-segment
levation myocardial infarction, when those with hemoglo-
in (Hb) values of 14 to 15 g/dl were used as the compar-
tor, 30-day cardiovascular mortality increased as Hb levels
See page 329
ell below 14 g/dl, with an adjusted odds ratio (OR) of 1.21
95% confidence interval [CI]: 1.12 to 1.30; p  0.001) for
ach 1 g/dl decrement in Hb. Similarly, among those with
on–ST-segment elevation ACS, using patients with Hb
evels of 15 to 16 g/dl as the reference, the likelihood of
ardiovascular death, subsequent myocardial infarction, or
ecurrent ischemia increased as the Hb fell below 11 g/dl,
ith an adjusted OR of 1.45 (95% CI: 1.33 to 1.58; p 
.001) for each 1 g/dl decrement in Hb. Considering PCI
atients, Lee et al. (1) observed a lower 1-year survival
mong 6,116 patients with anemia compared with those
ithout (adjusted hazard ratio [HR] for Hb 10 to 12 g/dl:
.5, 95% CI: 1.3 to 1.8, and for Hb 10 g/dl, 1.8, 95% CI:
.3 to 2.3; p  0.004).
Beyond anemia being associated with a worse cardiovascular
rognosis, there are additional caveats and limitations in caring
or such patients. For example, patients with baseline anemia
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
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ncluding Boston Scientific and Guidant.re known to be at increased risk for ACS- and PCI-related
leeding events. Manoukian et al. (3) found anemia to be a
trong independent predictor for major bleeding (OR: 1.87,
5% CI: 1.54 to 2.28; p  0.0001) in the ACUITY (Acute
atheterization and Urgent Intervention Triage Strategy)
tudy, which assessed bivalirudin versus heparin with platelet
Ib/IIIa inhibitors among 13,819 ACS-PCI patients. This and
ther recent studies (3,4) have also emphasized the relationship
etween bleeding and subsequent mortality. In the ACUITY
tudy, 30-day mortality was 7.3% versus 1.2% among patients
ith and without bleeding, respectively (OR: 7.55, 95% CI:
.68 to 12.18; p  0.0001). Therefore, as polypharmacy
nticoagulation strategies continue to emerge, it can be ex-
ected that bleeding will remain a pressing and persistent risk
mong ACS and PCI patients, particularly as the age of the
eneral population and related comorbidities (e.g., atrial fibril-
ation) increase (5).
For PCI patients, concerns regarding bleeding continue
eyond the catheterization laboratory and the index hospital-
zation because an ischemia-reduction benefit from long-term
ual antiplatelet therapy is established for ACS treatment and
eparately for drug-eluting stents (DES). A meta-analysis by
erebruany et al. (6) studied the bleeding risks associated with
ual-agent versus single-agent therapy and found that dual
ntiplatelet therapy was associated with an increased relative
isk of major (relative risk [RR]: 1.47, 95% CI: 1.36 to 1.60)
nd minor bleeding events (RR: 1.56, 95% CI: 1.47 to 1.66).
utting these multiple anemia- and bleeding-related issues
ogether, and synergized by concerns for stent thrombosis, it is
nderstandable why there is pause on the part of interventional
ardiologists when selecting drug-eluting versus bare-metal
tents among patients presenting with anemia.
The paper by Shishehbor et al. (7) in this issue of JACC:
ardiovascular Interventions provides some helpful insight and
ause for further reflection. In this first large-scale retrospective
tudy to specifically address the use of DES versus bare-metal
tents among anemic patients, the investigators suggest that
ES may be used safely in this patient group. Considering a
ultiyear interval with more than 11,000 PCI patients, 2,172
r roughly 20%, were found to have baseline anemia (as
efined byWorldHealth Organization). All-cause mortality at
1.8-year median follow-up was significantly lower for those
reated with DES in unadjusted and multivariable-adjusted
ox proportional models (HR: 0.66, 95% CI: 0.54 to 0.82; p
0.001). Considering anemia cut points according to hemat-
crit levels of 28%, 29% to 35%, and 35%, Shishehbor et
l. (7) observed mortality to be inversely proportional at
pproximately 35%, 25%, and 15%, respectively. For each of
hese hematocrit cut points, mortality was lower for patients
eceiving DES.
A concept that may be hypothesized from this manuscript
s that the heightened mortality risk associated with anemia
ay necessitate a more effectual form of PCI treatment.
hether any mortality benefit is from the antirestenotic
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338ffects of DES, the associated dual-antiplatelet therapy, or
ndefined factors is uncertain. Because numerous studies
ave shown that DES are particularly beneficial in higher
isk populations—patients with diabetes, end-stage renal
isease, and complicated coronary artery disease—it might
e plausible that DES provide a net mortality benefit to
hose with anemia despite increased bleeding risks. As new,
ore powerful antiplatelet agents such as prasugrel, cangre-
or, and ticagrelor (8,9) and newer generation DES are
eveloped, this hypothesis should be considered. Regard-
ess, prospective studies will be needed that collect impor-
ant information unavailable in the Shishehbor et al. (7)
ataset such as bleeding events, stent thrombosis, duration
f dual antiplatelet therapy, and other factors associated
ith the selection of bare-metal stents versus DES in
urrent practice.
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